Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Danuglipron

Stage Phase 1Stale

Sponsor Pfizer

Route oral

Class Oral small molecule

Mechanism oral small-molecule GLP-1 receptor agonist

Sources

registry, as of 2025-08-06Stale

https://clinicaltrials.gov/study/NCT06567327

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 82. Conditions Obesity. The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: * how the study medicine, danuglipron, is taken up into the blood * if the study medicine, danuglipron, changes

ClinicalTrials.gov NCT06567327 protocol and results modules

registry, as of 2025-01-20Stale

https://clinicaltrials.gov/study/NCT06568731

A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 23. Conditions Obesity. The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: * how the study medicine, danuglipron, is taken up into the blood * about the safety and tolerability of danugl

ClinicalTrials.gov NCT06568731 protocol and results modules

publication, as of 2025-08-06Stale

https://pubmed.ncbi.nlm.nih.gov/40539310/

to assess the efficacy, safety, and tolerability of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, in adults with obesity. Eligible participants (aged 18-75 years; with obesity, without diabetes) were randomized to receive danuglipron or placebo

PMID 40539310

Studies

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastati

Registry NCT06567327

Phase Phase 1

Status Completed

Enrollment 82

Start 2024-08-28

Primary completion 2025-03-16

Study completion 2025-04-14

Catalyst Primary completion. 2025-03-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cohort 1

Population Obesity

Cohort 2

Population Obesity

Cohort 3

Population Obesity

Cohort 4

Population Obesity

A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

Registry NCT06568731

Phase Phase 1

Status Completed

Enrollment 23

Start 2024-08-23

Primary completion 2024-12-18

Study completion 2024-12-18

Single Arm

Population Obesity